iBio, Inc. has released new preclinical data from an obese non-human primate (NHP) study for its Activin E antibody candidate, IBIO-610. A single dose of IBIO-610 reduced active Activin E levels in blood by 98% at week 4 and 97% at week 8, with levels falling below assay limits. These results suggest IBIO-610 could be a first-in-class, long-acting antibody for pathway inhibition. When combined with semaglutide, IBIO-610 demonstrated greater visceral and total fat loss while reducing lean mass loss by 73% compared to semaglutide alone. This indicates potential for IBIO-610 as a standalone therapy or a complementary treatment to GLP-1-based therapies. The full data will be presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan from September 28 to October 2.